Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ μL in the peripheral blood (PB) on the 4th day of mobilization. Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined. Results: The median CD34+ cell count in PB on the 4th day was 5.2/μL (0.1-13.4), which was determined to increase 206.6-fold (31.57- 49347) to 924.80 /μL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106). Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.
18 May 2026 in Journal of Current Hematology & Oncology Research
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.
26 February 2023 in Journal of Current Hematology & Oncology Research
Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors. Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA). Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group. Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.